FDA Oncologic Drugs Advisory Committee (ODAC) and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) supports 22-1 Talimogene Laherparepvec's approval. The FDA, although not held to the committee's consensus, has always done so in the past. Placing Amgen's Talimogene Laherparepvec as the first oncolytic therapy available in the US for the treatment of melanoma. [1]
|